-Recently broke 3 year resistance at 9c on high relative volume -Completed a low volume retrace -Now moving back towards 10c, expecting a break on 10c on good volume at some stage in the next 2-3 weeks -OBV gradually strengthening since late 2011, with strong upturn in last week or so - Buyers snapping up decent sized parcels from off screen
8.2c $8 million market cap $1.8 million cash
Cash at the end of September 2013 $1.78 million (up from $0.88 million at the end of June 2013).
Receipt of royalty income from bioMérieux during the quarter was $162,637. Minimum royalties for the full 2013 calendar year will total $US600,000.
LBT has an agreement with French diagnostics company bioMérieux to manufacture and market LBT’s MicroStreak® technology for the automated streaking of culture plates in microbiology testing.
LBT receives ongoing royalty payments for PREVI Isola, which has been installed in clinical laboratories in the US, Australia, China, Japan, Korea, the Middle East, UK and multiple European countries.
LBT's second breakthrough technology, APAS® (Automated Plate Assessment System) is nearing market.
LBT has entered into a Joint Venture with Hettich AG Switzerland to drive commercial development and global distribution of APAS instrumentation and software products.
